WF
AZN icon

Welch & Forbes’s AstraZeneca AZN Stock Holding History

Welch & Forbes’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,250
Closed -$525K – 387
2020
Q4 		$525K Hold
5,250
– – 0.01% 265
2020
Q3 		$575K Hold
5,250
– – 0.01% 240
2020
Q2 		$555K Buy
+5,250
New +$542K 0.01% 237

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Welch & Forbes's AZN Position: Q1 2021 in Review

Welch & Forbes sold out of AstraZeneca (AZN) in Q1 2021, closing a stake of 5,250 shares — an estimated $525K sold.

Welch & Forbes first reported a position in AZN in Q2 2020 and held it in 3 quarters. The position peaked at $575K in Q3 2020. 755 funds tracked by Wall St. Rank hold AZN as of Q1 2021.

  • Welch & Forbes reported no remaining AstraZeneca position as of Q1 2021 after selling out during the quarter.
  • Welch & Forbes sold 5,250 AstraZeneca shares in Q1 2021, an estimated $525K.
  • Welch & Forbes first reported a position in AstraZeneca in Q2 2020 and held it in 3 quarters.
  • Welch & Forbes's AstraZeneca position peaked at $575K in Q3 2020.
  • 755 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2021.

Based on Welch & Forbes's 13F filing for Q1 2021, filed 14 Apr 2021.